Patient Safety and Risk Management 2015
DOI: 10.1136/ejhpharm-2015-000639.331
|View full text |Cite
|
Sign up to set email alerts
|

PS-002 Importance of pharmacovigilance for maintaining hospital protocols including highly complex drugs: our own EGFR-TKI affair

Abstract: BackgroundTwo reversible tyrosine-kinase inhibitors of the epidermal growth factor receptor (EGFR-TKI) (A and B) were approved for the treatment of EGFR-mutant advanced non-small cell lung cancer (aNSCLC), with similar activity and results. Pharmacovigilance detected efficacy differences between A and B in our centre.PurposeTo define and possibly correct the cause of this finding.Material and methodsDrug A was considered our standard treatment for EGFR-mutant aNSCLC from April 2011 to March 2013, and was repla… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles